Summary
Clonidine was applied to the skin of healthy volunteers once weekly by means of a Transdermal Therapeutic System (TTS). The plasma concentration and renal excretion of clonidine, and its effects on mean arterial blood pressure (MAP) and heart rate (HR) were recorded for 7 days, followed by a three-day observation period when a second TTS was applied. Subjective side effects were semiquantitatively recorded. Four differents TTS formulations were tested; of which TTS-RP 600679 was the most effective. Following application of this formulation, the plasma level of the drug built-up up during the first 2 days and then remained stable for 120 h at therapeutic concentrations between 0.5 and 0.7 ng/ml; MAP was consistently reduced. During the steady state period the daily urinary clonidine excretion was in the same range as during chronic administration of Catapres tablets 0.15 mg every 12 h, or Catapres Perlongets 0.25 mg every 24 h. Transdermal clonidine applications renewed weekly provide the following therapeutic advantages: 1. patients are protected continuously throughout the entire steady state period; 2. daily fluctuations in plasma clonidine concentration are minimized, which may result in a marked reduction in side effects; and, 3. drug compliance should be improved.
Similar content being viewed by others
References
Anavekar SN, Jarrott B, Toscano W, Louis WJ (1982) Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. Eur J Clin Pharmacol 23:1–5
Arndts D, Warnkross H, Rominger KL, Justus H (1981a) Proof of the linearity of the pharmacokinetics of alinidine in man. Eur J Clin Pharmacol 21:201–207
Arndts D, Stähle H, Förster H-J (1981b) Development of a RIA for clonidine and its comparison with the reference methods. J Pharmacol Methods 6:295–307
Arndts D, Doevendans J, Kirsten R, Heintz B (1983) New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. Eur J Clin Pharmacol 24:21–30
Davies DS, Wing LMH, Reid JL, Neill E, Tippett P, Dollery CT (1977) Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 21:593–601
Dollery CT, Reid JL (1982) Double-blind comparison of the hypotensive, sedative and salivery flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforsch/Drug Res 32 [II]:984–987
Holm S (1979) A simple sequentially rejective multiple test Procedure. Scand J Stat 6:65–70
Houston MC (1981) Clonidine hydrochloride: Review of pharmacological and clinical aspects. Prog Cardiovasc Dis 23:337–350
Michaels AS, Chandrasekaran SK, Shaw JE (1975) Drug permeation through human skin: Theory and in vitro experimental measurement. Am Inst Chem Engineers J 21:985–996
Shaw JE, Chandrasekaran SK (1978) Controlled topical delivery of drugs for systemic action. Drug Metab Rev 8:223–233
Shaw JE, Urquhart J (1981) Transdermal drug administration — a nuisance becomes an opportunity. Br Med J 283:875–876
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arndts, D., Arndts, K. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine. Eur J Clin Pharmacol 26, 79–85 (1984). https://doi.org/10.1007/BF00546713
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546713